CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 120 enrolled
Drug / intervention
Fluocinolone Acetonidedrug
Likely dose
Fluocinolone Acetonide 0.2 μgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01304706
NCT01304706Phase 3Completed
CompareCT.gov

Fluocinolone Acetonide in Diabetic Macular Edema (FAME) Extension Study

Alimera Sciences·interventional·Posted Feb 25, 2011·Updated May 4, 2015

In Brief

A Phase 3 clinical trial evaluating Fluocinolone Acetonide for Diabetic Macular Edema. Completed, enrolled 120 participants across 1 site.

Detailed Summary

This study will assess the safety and utility of the new inserter for the administration of ILUVIEN in subjects with diabetic macular edema.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsDiabetic Macular Edema
CountriesUnited States
Collaborators--

Timeline

Phase 3CompletedFinished
2011201220132014201520162017201820192020202120222023202420252026
First PostedFeb 25, 2011
Enrollment StartApr 1, 2011
Primary CompletionNov 1, 2013
TodayJul 2, 2026
Enrollment to primary: 2.6 yearsPosted 15.4 years ago

Interventions

Fluocinolone Acetonidedrug

0.2 μg/day